MESOM
MCID: MST023
MIFTS: 57

Mesothelioma, Malignant (MESOM)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Mesothelioma, Malignant

MalaCards integrated aliases for Mesothelioma, Malignant:

Name: Mesothelioma, Malignant 56 52 73 29 6 43 39
Malignant Mesothelioma 12 52 54 15 17 71
Pleural Mesothelioma 58 17 71
Advanced Malignant Mesothelioma 12 71
Mesothelioma 71 32
Mesom 56 73
Malignant Mesothelioma, Susceptibility to 13
Asbestos-Related Malignant Mesothelioma 12
Diffuse Malignant Mesothelioma 12
Malignant Tumor of Mesothelium 12
Malignant Pleural Mesothelioma 71
Mesothelioma Diffuse Malignant 54
Mesothelioma, Somatic 56

Characteristics:

Orphanet epidemiological data:

58
pleural mesothelioma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

OMIM:

56
Inheritance:
somatic mutation

Miscellaneous:
etiologically linked to asbestos
may be seen in conjunction with other cancer syndromes (e.g., tdps )


HPO:

31
mesothelioma, malignant:
Inheritance somatic mutation


Classifications:

Orphanet: 58  
Rare respiratory diseases


External Ids:

Disease Ontology 12 DOID:1790
OMIM 56 156240
SNOMED-CT 67 62064005
ICD10 32 C45 C45.9
MESH via Orphanet 44 D008654
ICD10 via Orphanet 33 C45.0
UMLS via Orphanet 72 C0025500 C0812413 C1377913
Orphanet 58 ORPHA50251
MedGen 41 C0345967
UMLS 71 C0278752 C0345967 C0392400 more

Summaries for Mesothelioma, Malignant

NIH Rare Diseases : 52 Malignant mesothelioma is a form of cancer that develops in the thin layer of tissue that surrounds the lungs, chest wall, or abdomen. Signs and symptoms of the condition can vary and often depend on which area of the body is affected. Common features include abdominal bloating, abdominal pain, chest pain, coughing, fatigue, shortness of breath, and/or weight loss. Malignant mesothelioma is thought to be caused by long-term exposure to asbestos (a fire-resistant material that was once commonly found in insulation; ceiling and roof vinyls; cement; and automotive brake materials). Most people appear to be diagnosed with the condition approximately 30 years after being in contact with the asbestos. Unfortunately, there is generally no cure for malignant mesothelioma unless it is diagnosed at an early stage and can be surgically removed. If surgery is not an option, chemotherapy and/or radiation therapy may still be recommended to help alleviate some of the associated symptoms.

MalaCards based summary : Mesothelioma, Malignant, also known as malignant mesothelioma, is related to malignant peritoneal mesothelioma and pericardial mesothelioma, and has symptoms including fatigue, dyspnea and chest pain. An important gene associated with Mesothelioma, Malignant is BCL10 (BCL10 Immune Signaling Adaptor), and among its related pathways/superpathways are MicroRNAs in cancer and Cytoskeletal Signaling. The drugs Deoxyglucose and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include lung, testis and t cells, and related phenotypes are pleural effusion and weight loss

Disease Ontology : 12 A cell type cancer that has material basis in mesothelial tissue that develops from the thin layer of tissue that covers many of the internal organs.

OMIM : 56 Malignant mesothelioma is an aggressive neoplasm of the serosal lining of the chest etiologically linked to asbestos. It is diagnosed in approximately 2,000 to 3,000 individuals annually in the United States, most of whom die within 2 years of diagnosis (summary by Bott et al., 2011). See also 614327 for a tumor predisposition syndrome that may contribute to the development of malignant mesothelioma upon asbestos exposure and is caused by germline mutation in the BAP1 gene (603089) on chromosome 3p21. (156240)

UniProtKB/Swiss-Prot : 73 Mesothelioma, malignant: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos.

Wikipedia : 74 Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the... more...

Related Diseases for Mesothelioma, Malignant

Diseases in the Benign Mesothelioma family:

Mesothelioma, Malignant Benign Intermediate Mesothelioma

Diseases related to Mesothelioma, Malignant via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 716)
# Related Disease Score Top Affiliating Genes
1 malignant peritoneal mesothelioma 33.5 NF2 MUC1 BAP1
2 pericardial mesothelioma 33.4 MUC1 CALB2
3 malignant pleural mesothelioma 33.3 WT1 THBD PDPN NKX2-1 NF2 MUC1
4 peritoneal mesothelioma 33.2 WT1 THBD NF2 MUC1 CALB2 BAP1
5 malignant epithelial mesothelioma 33.1 WT1 THBD CALB2
6 malignant biphasic mesothelioma 32.8 WT1 THBD MSLN CALB2
7 benign mesothelioma 32.6 WT1 CALB2
8 sarcomatoid mesothelioma 32.4 WT1 THBD PDPN NKX2-1 MUC1 MSLN
9 small cell carcinoma 31.2 WT1 NKX2-1 MUC1
10 lung cancer susceptibility 3 31.1 THBD NKX2-1 MUC1 MSLN MIR885 MIR582
11 carcinosarcoma 31.1 WT1 MUC1 CALB2
12 angiosarcoma 31.1 PDPN MUC1 CALB2
13 thymic carcinoma 31.0 NKX2-1 MUC1 CALB2
14 benign peritoneal mesothelioma 31.0 PDPN MUC1 MSLN CALB2
15 neurilemmoma 31.0 NF2 MUC1 CALB2
16 lymphohistiocytoid mesothelioma 30.9 THBD CALB2
17 pleural disease 30.9 MSLN CALB2 BAP1
18 ovary adenocarcinoma 30.9 WT1 MUC1 MSLN CALB2
19 papillary carcinoma 30.8 NKX2-1 MUC1 CALB2
20 secretory meningioma 30.8 NF2 MUC1
21 asbestosis 30.8 WT1 THBD MUC1 MSLN CALB2
22 endosalpingiosis 30.8 WT1 MUC1 CALB2
23 peritoneal serous adenocarcinoma 30.7 WT1 CALB2
24 ovarian cystadenocarcinoma 30.7 MUC1 MIR483 CALB2
25 renal cell carcinoma, nonpapillary 30.7 WT1 NKX2-1 MUC1 MSLN MIR885 MIR584
26 pleomorphic carcinoma 30.7 PDPN NKX2-1 CALB2
27 peritoneum cancer 30.7 WT1 NF2 MSLN CALB2 BAP1
28 pericardium cancer 30.7 WT1 MSLN CALB2
29 renal cell carcinoma, papillary, 1 30.6 WT1 PDPN NF2 BAP1
30 pancreatic ductal adenocarcinoma 30.6 MUC1 MSLN MIR615 MIR483 MIR203A
31 lymphangitis 30.6 PDPN NKX2-1
32 pneumothorax 30.5 NKX2-1 MUC1 CALB2
33 monophasic synovial sarcoma 30.5 MUC1 CALB2
34 adenomatoid tumor 30.5 WT1 THBD NKX2-1 CALB2
35 ovarian brenner tumor 30.5 WT1 THBD
36 clear cell renal cell carcinoma 30.5 WT1 MUC1 CALB2 BAP1
37 ovarian serous cystadenocarcinoma 30.5 MUC1 MIR483 CALB2
38 sarcoma, synovial 30.5 WT1 MUC1 CALB2
39 benign ependymoma 30.4 NF2 MUC1 LINC01194
40 cystadenofibroma 30.4 WT1 MUC1 CALB2
41 pleural cancer 30.4 WT1 PDPN NF2 MSLN CALB2 BAP1
42 malignant peripheral nerve sheath tumor 30.4 WT1 NF2 MUC1
43 biphasic synovial sarcoma 30.4 MUC1 CALB2
44 fibrous meningioma 30.4 NF2 MUC1
45 benign teratoma 29.9 NKX2-1 CALB2
46 rhabdoid tumor predisposition syndrome 1 29.8 WT1 MUC1
47 benign multicystic peritoneal mesothelioma 12.5
48 peritoneal cystic mesothelioma 12.5
49 ovarian malignant mesothelioma 12.3
50 bap1 tumor predisposition syndrome 12.0

Graphical network of the top 20 diseases related to Mesothelioma, Malignant:



Diseases related to Mesothelioma, Malignant

Symptoms & Phenotypes for Mesothelioma, Malignant

Human phenotypes related to Mesothelioma, Malignant:

58 31 (show all 19)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pleural effusion 58 31 hallmark (90%) Very frequent (99-80%) HP:0002202
2 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
3 respiratory distress 58 31 frequent (33%) Frequent (79-30%) HP:0002098
4 cough 58 31 frequent (33%) Frequent (79-30%) HP:0012735
5 chest pain 58 31 frequent (33%) Frequent (79-30%) HP:0100749
6 dysphagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002015
7 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
8 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716
9 fourth cranial nerve palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0007011
10 obstruction of the superior vena cava 58 31 occasional (7.5%) Occasional (29-5%) HP:0031041
11 abnormal cardiovascular system physiology 31 occasional (7.5%) HP:0011025
12 dyspnea 58 Frequent (79-30%)
13 abnormality of the thorax 58 Frequent (79-30%)
14 abnormality of the pleura 58 Frequent (79-30%)
15 functional respiratory abnormality 58 Occasional (29-5%)
16 abnormal lung morphology 58 Occasional (29-5%)
17 abnormality of cardiovascular system physiology 58 Occasional (29-5%)
18 constitutional symptom 58 Frequent (79-30%)
19 malignant mesothelioma 31 HP:0100001

Symptoms via clinical synopsis from OMIM:

56
Respiratory Lung:
mesothelioma, malignant

Neoplasia:
mesothelioma

Clinical features from OMIM:

156240

UMLS symptoms related to Mesothelioma, Malignant:


fatigue, dyspnea, chest pain, chills, malaise

Drugs & Therapeutics for Mesothelioma, Malignant

Drugs for Mesothelioma, Malignant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 311)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Deoxyglucose Phase 4
2
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
3
Methylcobalamin Approved, Investigational Phase 2, Phase 3 13422-55-4
4
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
6
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Ipilimumab Approved Phase 3 477202-00-9
9
Nintedanib Approved Phase 2, Phase 3 656247-17-5 56843413
10
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
11
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
12 Ranpirnase Investigational Phase 3 196488-72-9
13
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
14 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
15 Vitamins Phase 2, Phase 3
16 Micronutrients Phase 3
17 Vitamin B 12 Phase 2, Phase 3
18 Trace Elements Phase 3
19 Nutrients Phase 3
20 Vitamin B12 Phase 2, Phase 3
21 BB 1101 Phase 3
22 Autonomic Agents Phase 3
23 Interferon-alpha Phase 3
24 Interferon alpha-2 Phase 3
25 Vinca Alkaloids Phase 3
26
Vinblastine Approved Phase 2 865-21-4 13342 241903
27
Megestrol acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 595-33-5 11683
28
Heparin Approved, Investigational Phase 2 9005-49-6 772 46507594
29
Ibuprofen Approved Phase 2 15687-27-1 3672
30
Selenious acid Approved, Investigational Phase 1, Phase 2 7783-00-8
31
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
32
Belinostat Approved, Investigational Phase 2 866323-14-0
33
Epirubicin Approved Phase 2 56420-45-2 41867
34
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
35
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
36
Axitinib Approved, Investigational Phase 1, Phase 2 319460-85-0 6450551
37
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
38
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
39
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 40926 439693
40
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
41
Zoledronic Acid Approved Phase 2 118072-93-8 68740
42
Tamoxifen Approved Phase 2 10540-29-1 2733526
43
Sodium citrate Approved, Investigational Phase 2 68-04-2
44
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
45
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
46
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
47
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
48
Raltitrexed Approved, Investigational Phase 1, Phase 2 112887-68-0 104758
49
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
50
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316

Interventional clinical trials:

(show top 50) (show all 468)
# Name Status NCT ID Phase Drugs
1 Pharmacokinetics of Carboplatin After Adjusted Dosing for High BMI, Low Serum Creatinine, and Maximal Renal Function Unknown status NCT02103244 Phase 4 Carboplatin
2 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
3 Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
4 Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response Recruiting NCT03655834 Phase 4 Pemetrexed
5 Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response Recruiting NCT03655821 Phase 4 Pemetrexed
6 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
7 ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
8 Phase III Study of Tomudex and Cisplatin Versus Cisplatin in Malignant Pleural Mesothelioma Completed NCT00004920 Phase 3 cisplatin;raltitrexed
9 A Randomized Controlled Trial of Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
10 A Single-Blind Randomized Phase III Trial of MTA Plus Cisplatin Versus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00005636 Phase 3 cisplatin;pemetrexed disodium
11 A Randomized Phase 3 Trial Comparing ALIMTA Plus Best Supportive Care Versus Best Supportive Care Alone in Previously Treated Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma Completed NCT00190762 Phase 3 Pemetrexed
12 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy Completed NCT00128102 Phase 3 vorinostat;Placebo
13 A Randomized Study to Assess Whether Radiotherapy Prevents Skin Lumps at Sites Where Needles or Tubes Have Been Inserted in Patients With Malignant Mesothelioma Completed NCT00006231 Phase 3
14 NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM) Completed NCT01098266 Phase 3 NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
15 A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM) Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
16 Prospective Randomised Controlled Trial of Video-Assisted Thoracoscopic (VAT) Cytoreductive Pleurectomy Compared to Talc Pleurodesis in Patients With Suspected or Proven Malignant Mesothelioma Completed NCT00821860 Phase 3
17 Phase III Trial of Single-Agent Pemetrexed (Alimta®) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2 Completed NCT01836575 Phase 3 Pemetrexed;Carboplatin
18 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
19 Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies Completed NCT02349412 Phase 3
20 Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesotheliomato Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study) Recruiting NCT02709512 Phase 2, Phase 3 ADI-PEG 20 plus Pem Cis
21 A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma Recruiting NCT03762018 Phase 3 Carboplatin;Pemetrexed;Bevacizumab;Atezolizumab
22 A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Recruiting NCT02784171 Phase 2, Phase 3 Cisplatin;Pemetrexed;Pembrolizumab
23 A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma Recruiting NCT03710876 Phase 3 Celecoxib Oral Product;Gemcitabine
24 CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma Recruiting NCT03063450 Phase 3 Nivolumab
25 A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy Recruiting NCT03610360 Phase 2, Phase 3 MesoPher
26 A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma Active, not recruiting NCT02991482 Phase 3 Pembrolizumab;Gemcitabine;Vinorelbine
27 A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Active, not recruiting NCT02899299 Phase 3 Pemetrexed;Cisplatin;Carboplatin
28 Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) Not yet recruiting NCT04158141 Phase 3 Carboplatin;Cisplatin;Pemetrexed;Pemetrexed Disodium
29 LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma Terminated NCT01907100 Phase 2, Phase 3 Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
30 PIT: A Phase III Randomised Trial of Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Following Invasive Chest Wall Intervention Terminated NCT01604005 Phase 3
31 A Randomized Phase III Trial to Compare the Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication for Mesothelioma or Other Pathologies Withdrawn NCT02511600 Phase 3
32 A Randomized Stratified Multicentre Phase II Clinical Trial of Single Agent ADI-PEG 20TM (Pegylated Arginine Deiminase) in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2 ADI-PEG 20
33 Aggressive Multi-Modality Management of Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
34 Four Versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelioma; a Randomized Phase II Study Unknown status NCT02497053 Phase 2 pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
35 A Pilot And Feasibility Trial Evaluating Two Different Chemotherapy Regimens In Combination With Intrapleural Adenoviral-Mediated Interferon-Alpha Gene Transfer For Malignant Pleural Mesothelioma Unknown status NCT01119664 Phase 1, Phase 2 SCH 721015
36 Phase II Study of Six Hours, Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma. Unknown status NCT01869023 Phase 2 Gemcitabine;Cisplatin
37 "Phase II Study: Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma " Unknown status NCT00886028 Phase 2 Liposomal doxorubicin;Cisplatin
38 A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma Unknown status NCT02303899 Phase 2 Gemcitabine;Imatinib mesylate
39 Phase II, A Study of Lung-Sparing Combined Modality Protocol for the Treatment for Malignant Pleural Mesothelioma: The Columbia Protocol Unknown status NCT00859495 Phase 2 Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
40 A Phase II Trial to Assess the Safety, Immunological Activity of TroVax® Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2 Pemetrexed;Cisplatin;Dexamethasone
41 A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit Unknown status NCT00551252 Phase 2 Imatinib mesylate plus Gemcitabine
42 Randomized Feasibility Study Of Active Symptom Control With Or Without Chemotherapy In The Treatment Of Patients With Mesothelioma Unknown status NCT00030459 Phase 2 cisplatin;mitomycin C;vinblastine sulfate;vinorelbine tartrate
43 A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1 Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
44 Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
45 Phase I/II Study of High-Dose Megestrol in Breast or Endometrial Carcinoma or Mesothelioma Unknown status NCT00002465 Phase 1, Phase 2 megestrol acetate
46 Phase I-Ib Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Advanced or Metastatic Cancer Suitable for a Carboplatin and Pemetrexed Regimen as Part of Their Specific Therapy Unknown status NCT02049060 Phase 1, Phase 2 Tivantinib
47 Trial of Sorafenib in Malignant Mesothelioma Previously Treated With Platinum-based Chemotherapy Unknown status NCT00794859 Phase 2 Sorafenib
48 A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
49 A Second-line, Single Arm, Phase II Clinical Study With Tremelimumab, a Fully Human Anti-CTLA-4 Monoclonal Antibody as Monotherapy in Patients With Unresectable Malignant Mesothelioma Unknown status NCT01649024 Phase 2 Tremelimumab
50 A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012 Unknown status NCT01655888 Phase 2 Tremelimumab

Search NIH Clinical Center for Mesothelioma, Malignant

Cochrane evidence based reviews: mesothelioma, malignant

Genetic Tests for Mesothelioma, Malignant

Genetic tests related to Mesothelioma, Malignant:

# Genetic test Affiliating Genes
1 Mesothelioma, Malignant 29 BCL10 WT1

Anatomical Context for Mesothelioma, Malignant

MalaCards organs/tissues related to Mesothelioma, Malignant:

40
Lung, Testis, T Cells, Heart, Thyroid, Kidney, Breast

Publications for Mesothelioma, Malignant

Articles related to Mesothelioma, Malignant:

(show top 50) (show all 4745)
# Title Authors PMID Year
1
Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. 54 61 56
7494231 1995
2
A cluster of familial malignant mesothelioma with del(9p) as the sole chromosomal anomaly. 61 56
12419589 2002
3
Neurofibromatosis 2 and malignant mesothelioma. 61 56
12136076 2002
4
Familial malignant mesothelioma. 61 56
11734267 2001
5
Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. 61 56
11273069 2001
6
Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. 61 56
9927061 1999
7
Familial pleural malignant mesothelioma: clustering in three sisters and one cousin. 61 56
9751275 1998
8
Familial mesothelioma: review and family study. 61 56
3967217 1985
9
Malignant mesothelioma in two pairs of siblings: is there a hereditary predisposing factor? 61 56
6723827 1984
10
Familial clustering of malignant mesothelioma. 61 56
7379039 1980
11
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. 56
21642991 2011
12
CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. 61 46
19396864 2009
13
Lack of Bcl10 mutations in testicular germ cell tumours and derived cell lines. 6
10408400 1999
14
Lack of BCL10 mutations in germ cell tumors and B cell lymphomas. 6
10380920 1999
15
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 6
9989495 1999
16
Asbestos and mesothelioma: genetic lessons from a tragedy. 56
7479890 1995
17
Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. 6
8298644 1993
18
Asbestos-contaminated nappies and familial mesothelioma. 56
2564999 1989
19
Familial mesothelioma: a report of two families. 56
2914699 1989
20
Familial mesothelioma after intense asbestos exposure at home. 56
660896 1978
21
An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgüp in Anatolia. 56
663877 1978
22
Household-contact asbestos neoplastic risk. 56
1069520 1976
23
Ultrastructure and observations on the histogenesis of mesotheliomas, "adenomatoid tumors", of the female genital tract. 6
4332312 1972
24
Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model. 54 61
20072072 2010
25
9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. 54 61
20518890 2010
26
Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. 54 61
19523712 2010
27
Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. 54 61
20146302 2010
28
Well-differentiated papillary mesothelioma with invasion to the chest wall. 54 61
19880210 2010
29
Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. 54 61
20131968 2010
30
[Malignant peritoneal mesothelioma]. 54 61
20445731 2010
31
Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. 54 61
19740516 2010
32
Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. 54 61
19843662 2009
33
Malignant mesothelioma of the greater omentum mimicking omental infarction: a case report. 54 61
19824125 2009
34
Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. 54 61
19451229 2009
35
An EMA negative, desmin positive malignant mesothelioma: limitations of immunohistochemistry? 54 61
19561235 2009
36
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. 54 61
19380521 2009
37
Serum and pleural fluid biomarkers for mesothelioma. 54 61
19417672 2009
38
Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. 54 61
19285954 2009
39
Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma. 54 61
18838334 2009
40
Placenta growth factor is a survival factor for human malignant mesothelioma cells. 54 61
19505392 2009
41
[A case of IL-6 producing malignant mesothelioma of abdomen with thrombocytosis]. 54 61
19346724 2009
42
Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. 54 61
19289587 2009
43
Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers. 54 61
19261093 2009
44
Clinical utility of diagnostic markers for malignant pleural mesothelioma. 54 61
19522163 2009
45
A binding domain on mesothelin for CA125/MUC16. 54 61
19075018 2009
46
The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells. 54 61
19176370 2009
47
Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies. 54 61
19152187 2009
48
Osteopontin levels in an asbestos-exposed population. 54 61
19174489 2009
49
Interaction of onconase with the human ribonuclease inhibitor protein. 54 61
18930025 2008
50
mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. 54 61
18511708 2008

Variations for Mesothelioma, Malignant

ClinVar genetic disease variations for Mesothelioma, Malignant:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 WT1 NM_024426.6(WT1):c.1303C>T (p.Arg435Ter)SNV Pathogenic 3497 rs121907906 11:32414263-32414263 11:32392717-32392717
2 WT1 NM_024426.6(WT1):c.1036A>G (p.Ser346Gly)SNV Pathogenic 3499 rs121907908 11:32421571-32421571 11:32400025-32400025
3 BCL10 NM_003921.5(BCL10):c.499dup (p.Ser167fs)duplication Pathogenic 6250 rs387906350 1:85733512-85733513 1:85267829-85267830
4 BCL10 NM_003921.5(BCL10):c.136del (p.Ile46fs)deletion Pathogenic 6263 rs387906351 1:85736511-85736511 1:85270828-85270828
5 WT1 NM_024426.6(WT1):c.314C>G (p.Ala105Gly)SNV Uncertain significance 476699 rs948061247 11:32456593-32456593 11:32435047-32435047

Copy number variations for Mesothelioma, Malignant from CNVD:

7 (show all 35)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13405 1 1 2300000 Loss Malignant mesothelioma
2 21838 1 16200000 28000000 Loss Malignant mesothelioma
3 33950 1 50700000 61300000 Amplification Malignant mesothelioma
4 35952 1 69700000 116100000 Loss Malignant mesothelioma
5 35954 1 69700000 116100000 Loss CLCA1 Malignant mesothelioma
6 35956 1 69700000 116100000 Loss CLCA2 Malignant mesothelioma
7 35958 1 69700000 116100000 Loss CLCA3 Malignant mesothelioma
8 35960 1 69700000 116100000 Loss CLCA4 Malignant mesothelioma
9 35962 1 69700000 116100000 Loss COL11A1 Malignant mesothelioma
10 35964 1 69700000 116100000 Loss TGFBR3 Malignant mesothelioma
11 35966 1 69700000 120600000 Loss Malignant mesothelioma
12 37056 1 84900000 107200000 Loss Malignant mesothelioma
13 69952 12 56600000 58100000 Gain Malignant mesothelioma
14 75172 13 17900000 45800000 Loss BRCA2 Malignant mesothelioma
15 85738 14 50900000 107349540 Loss CCNK Malignant mesothelioma
16 85740 14 50900000 107349540 Loss CDKN3 Malignant mesothelioma
17 113645 17 44900000 81195210 Gain ERN1 Malignant mesothelioma
18 113647 17 44900000 81195210 Gain MAP3K3 Malignant mesothelioma
19 113649 17 44900000 81195210 Gain PRKCA Malignant mesothelioma
20 113651 17 44900000 81195210 Gain SMARCD2 Malignant mesothelioma
21 175422 3 39400000 63700000 Loss CACNA2D3 Malignant mesothelioma
22 175424 3 39400000 63700000 Loss CTNNB1 Malignant mesothelioma
23 175426 3 39400000 63700000 Loss MLH1 Malignant mesothelioma
24 175771 3 44100000 44200000 Loss Malignant mesothelioma
25 187512 4 50400000 191154276 Loss Malignant mesothelioma
26 191705 5 1 48400000 Gain Malignant mesothelioma
27 204729 6 114600000 118300000 Loss HDAC2 Malignant mesothelioma
28 204731 6 114600000 118300000 Loss MARCKS Malignant mesothelioma
29 217075 7 1 4500000 Gain Malignant mesothelioma
30 234871 8 139900000 146364022 Gain Malignant mesothelioma
31 250026 9 19900000 25600000 Loss C9orf14 Malignant mesothelioma
32 250029 9 19900000 25600000 Loss CDKN2A Malignant mesothelioma
33 250031 9 19900000 25600000 Loss CDKN2B Malignant mesothelioma
34 250069 9 19900000 33200000 Loss Malignant mesothelioma
35 251883 9 33200000 36300000 Gain Malignant mesothelioma

Expression for Mesothelioma, Malignant

Search GEO for disease gene expression data for Mesothelioma, Malignant.

Pathways for Mesothelioma, Malignant

Pathways related to Mesothelioma, Malignant according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.75 MIR615 MIR483 MIR345 MIR203A
2 11.41 PDPN NF2 MUC1 BAP1

GO Terms for Mesothelioma, Malignant

Cellular components related to Mesothelioma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 filopodium membrane GO:0031527 8.62 PDPN NF2

Molecular functions related to Mesothelioma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR582 MIR483 MIR345 MIR203A

Sources for Mesothelioma, Malignant

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....